Abstract
Advances in the treatment of metastatic melanoma significantly affected the prognosis of patients with metastatic disease. Currently therapy is based on two basic therapeutic principles, namely immunotherapy with monoclonal antibodies anti-CTLA-4 and anti-PD-1 and targeted oncology therapy with BRAF inhibitors alone or in combination with MEK inhibitors.
The knowledge of these therapeutic modalities leads to combination treatment, which is subject of a number of clinical trials. The work provides an overview of key contemporary knowledge and outline new options in the treatment of metastatic melanoma